An interventional study of Social Sharing-Based Mobile Application and Usual Care with Psycho-educational Manual in Head and Neck Squamous Cell Carcinoma, sponsored by West China Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by West China Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Squamous Cell Carcinoma of Head and Neck by West China Hospital — 11 open to participants now, 12 under way, none of them phase 3. Squamous Cell Carcinoma of Head and Neck · West China Hospital.
Among the 21 studies in Squamous Cell Carcinoma of Head and Neck by West China Hospital, this one is the 3rd largest by planned enrollment of the 20 interventional ones that give a count, is one of 9 that started in 2026, is the only one with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 21st registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →11 of the 21 studies in Squamous Cell Carcinoma of Head and Neck by West China Hospital are open now, in 1 country. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 18–70
West China Hospital · Sites in China
Ages 18+
West China Hospital · Sites in China
Ages 18–75
West China Hospital · Sites in China
Ages 18+
West China Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 11
First in 2022; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 14 across the 20 interventional studies, 0 across the 1 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
West China Hospital is the lead sponsor of 501 studies on the registry; 246 are open to participants now.
10 of the studies in Squamous Cell Carcinoma of Head and Neck by West China Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07492914West China HospitalNeoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma | 2026-12-31 |
| NCT07567235West China HospitalClinical Study of CFH Protein Via Ice Microneedles for Radiation-Induced Skin Fibrosis | 2027-03-01 |
| NCT07457281West China HospitalGV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study | 2027-04-01 |
| NCT07572864West China HospitalNeoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC | 2027-05-01 |
| NCT07565740West China HospitalIntranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC | 2027-05-10 |
Add all 10 to your calendar (.ics) → With an account.
Among the 21 studies in Squamous Cell Carcinoma of Head and Neck by West China Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Head and neck cancer patients often experience significant anxiety and depression during radiation therapy, which can affect their quality of life and treatment adherence. However, traditional psychological support is limited by resource constraints and accessibility. This study aims to evaluate whether a mobile application based on social sharing and peer interaction can improve psychological distress in patients with head and neck squamous cell carcinoma (HNSCC) undergoing radiotherapy.
This is a prospective, randomized, parallel-group, open-label trial. A total of 120 participants will be randomly assigned in a 1:1 ratio to either the immediate intervention group or a waitlist control group. Participants in the intervention group will use a dedicated app featuring daily sharing, peer interaction (anonymous comments, likes, private messaging), psychoeducational resources, and reminders. The control group will receive a printed psychoeducational booklet during the initial phase and will gain access to the app after the primary endpoint assessment.
The primary outcome is the change in anxiety score (HADS-A) from baseline to completion of radiotherapy. Secondary outcomes include depression scores (HADS-D), radiotherapy interruption rate, app engagement, and severe psychological distress prevalence. Exploratory outcomes include quality of life (EORTC QLQ-C30, H\&N35), readmission rate, adverse event severity (CTCAE v5.0), and biological markers (e.g., cortisol, IL-6, CRP).
The study is expected to run from April 2026 to August 2027. Findings may inform scalable digital psychosocial interventions for cancer patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive immediate access to the social sharing-based mobile app intervention. The active intervention phase begins at radiotherapy initiation and lasts for 8 weeks, through 4 weeks post-radiotherapy, during which participants are encouraged to post at least 2 shares and complete at least 3 interactions per week. App access remains open thereafter for voluntary use through 12 weeks post-radiotherapy.
Other: Social Sharing-Based Mobile Application
Participants receive a printed psychoeducational booklet during the initial phase and will gain access to the same app intervention after the primary endpoint assessment (radiotherapy completion).
Other: Usual Care with Psycho-educational Manual
Mobile app with five modules: daily sharing, anonymous peer interaction, psychoeducational resources, task reminders, and professional support. Participants post ≥2 shares and interact ≥3 times weekly for 8 weeks. Content moderated by research assistants.
Participants receive standard radiotherapy care and a printed psychological adjustment manual, without access to the social sharing APP during the initial intervention phase.
Change in Anxiety Score (HADS-A)
Change in the Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A) score from baseline to completion of radiotherapy. HADS-A consists of 7 items, each scored 0-3, with total score ranging from 0 to 21. Higher scores indicate more severe anxiety symptoms.
Time frame: Baseline (within 1 week pre-radiotherapy) through 12 weeks post-radiotherapy
Change in Depression Score (HADS-D)
Change in the Hospital Anxiety and Depression Scale-Depression subscale (HADS-D) score from baseline to completion of radiotherapy. HADS-D consists of 7 items, each scored 0-3, with total score ranging from 0 to 21. Higher scores indicate more severe depressive symptoms.
Time frame: Baseline (within 1 week pre-radiotherapy) through 12 weeks post-radiotherapy
Change in Combined HADS Total Score
Change in the combined Hospital Anxiety and Depression Scale total score (HADS-A + HADS-D, range 0-42) from baseline to completion of radiotherapy. Higher scores indicate greater overall psychological distress.
Time frame: Baseline (within 1 week pre-radiotherapy) through 12 weeks post-radiotherapy
Prevalence of Severe Psychological Distress
Proportion of participants with a combined HADS total score ≥ 15 at radiotherapy completion.
Time frame: Within 7 days post-radiotherapy
Radiotherapy Interruption Rate
Proportion of participants with unplanned radiotherapy delay of ≥5 days beyond the scheduled treatment period (including weekends and holidays) due to any cause.
Time frame: From the first planned radiotherapy fraction through completion or early discontinuation of radiotherapy
APP Engagement Rate
Proportion of participants in the intervention group with an average login frequency of \>2 times per week during the active intervention period.
Time frame: Baseline (within 1 week pre-radiotherapy) through 12 weeks post-radiotherapy
Change From Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life Score
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life scale consists of two items. Raw scores will be linearly transformed to a 0-to-100 scale according to the EORTC QLQ-C30 scoring manual. Higher scores indicate better global health status and quality of life. Change from baseline will be calculated at each post-baseline assessment, with a positive change indicating improvement.
Time frame: Baseline (within 1 week pre-radiotherapy) through 12 weeks post-radiotherapy
EORTC QLQ-H&N35 Symptom Scale and Single-Item Scores
Head and neck cancer-specific symptoms and problems will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Cancer Module (EORTC QLQ-H\&N35). The questionnaire includes multi-item scales assessing pain, swallowing, senses, speech, social eating, social contact, and sexuality, as well as single items assessing additional head and neck cancer-related symptoms and problems. Scale and single-item scores will be linearly transformed to a 0-to-100 scale according to the EORTC scoring manual. Higher scores indicate greater symptom burden or more severe problems.
Time frame: Baseline (within 1 week pre-radiotherapy) through 12 weeks post-radiotherapy
Number and Proportion of Participants With Radiotherapy-Related Adverse Events Assessed by CTCAE Version 5.0
Radiotherapy-related adverse events will be identified and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. For each participant, adverse events will be summarized by event type and maximum CTCAE grade. Results will be reported as the number and proportion of participants experiencing each adverse event and each severity grade. CTCAE grades are defined as Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling; and Grade 5, death related to an adverse event.
Time frame: From initiation of radiotherapy through 12 weeks after completion of radiotherapy
Plan to share: No
Started Aug 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.
Of 115 non-industry interventional studies with no phase under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 90. This study's planned 11 months is below that.
Counting every sponsor, half of 126 studies reached it within 59 months; a quarter within 34 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Squamous Cell Carcinoma of Head and Neck →